The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Addition of venetoclax to hyper-CVAD-nelarabine-pegAsp for T-ALL/LBL: 2-year follow-up from the phase II trial
|
Venetoclax is a BCL-2 inhibitor that demonstrated activity in preclinical and early-phase studies in patients with ETP-ALL/LBL. A phase II trial (NCT00501826) evaluated the outcomes of hyper-CVAD-nelarabine-pegAsp (original cohort) in adults with untreated T-ALL/LBL. In the latest protocol iteration of this trial, venetoclax was added to the induction/consolidation regimen (venetoclax cohort). The long-term results published in Leukemia by Ravandi et al.1 assessed the outcomes of adding venetoclax to the original cohort in 145 patients. The primary endpoint was the improvement in 2-year PFS and OS with venetoclax. |
| Key learnings |
| With a median follow-up of 62.4 months, 5-year PFS, DoR, and OS were 63.7%, 72.0%, and 66.2%, respectively, in the whole cohort. |
| The venetoclax cohort demonstrated higher 2-year PFS (87.9% vs 64.1%; p = 0.03) and DoR (93.6% vs 69.2%; p = 0.005) vs the original cohort. |
| The venetoclax cohort showed improved 2-year OS vs the original cohort (87.8% vs 73.9; p = 0.16). |
| Febrile neutropenia was the most common serious AE (60%); neurotoxicity and thromboembolic events were reported at lower rates (7.6% and 5.5%, respectively). |
| Overall, the promising efficacy and safety data suggest that the addition of venetoclax to hyper-CVAD-nelarabine-pegAsp could be a viable treatment option for adult patients with T-ALL/LBL. |
Abbreviations: DoR, duration of response; ETP, early T-cell precursor; hyperCVAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; LBL, lymphoblastic lymphoma; pegAsp, pegylated asparaginase; PFS, progression-free survival; OS, overall survival; T-ALL, T-cell acute lymphoblastic leukemia.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content